Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Biologicals. 2013 Oct 10;41(6):10.1016/j.biologicals.2013.09.005. doi: 10.1016/j.biologicals.2013.09.005

Fig. 3.

Fig. 3

Serological screening for antibodies against PCV-2 in human serum samples. Immunoreactivity against the PCV-2-CAP-Δ1 fusion protein was determined by LIPS in serum samples from 40 US human blood donors, 40 cystic fibrosis patients (CF Patients) taking porcine enzyme supplements, 9 xenotransplant patients (Human Xenotran.) who had received porcine β-cells, 20 horses, and 20 cows. Two additional PCV-2-infected porcine serum samples were included as positive controls. The geometric mean and 95% confidence interval of the antibody level are also denoted. The dashed line represents the previously described diagnostic cut-off used in Fig. 2B.